Skip to main content

Advertisement

Table 2 Detailed Parameters of Scenarios 1 to 4 in the Simulation Study

From: A comparison of estimators from self-controlled case series, case-crossover design, and sequence symmetry analysis for pharmacoepidemiological studies

Scenarios β X β C1 β C2 β C3 β C1C2 β C2C3 α TR β TR Et C (Days)a
1 log(1.0) log(2.0) log(3.0) log(1.0) log(5.0) log(1.0) 15
  log(3.0)       
  log(10.0)       
2 log(1.0) log(2.0) log(3.0) log(5.0) log(1.0) log(1.0) 15
  log(3.0)       
  log(10.0)       
  log(3.0) log(2.0) log(3.0) log(0.2) log(1.0) log(1.0) 15
     log(0.5)    
     log(2.0)    
  log(3.0) log(2.0) log(3.0) log(5.0) log(1.0) log(1.0) 5
        10
        20
        30
3 log(1.0) log(2.0) log(3.0) log(5.0) log(1.0) log(5.0) 15
  log(3.0)       
  log(10.0)       
  log(3.0) log(2.0) log(3.0) log(5.0) log(1.0) log(0.2) 15
       log(0.5)  
       log(2.0)  
  log(3.0) log(2.0) log(3.0) log(5.0) log(1.0) log(5.0) 5
        10
        20
        30
4 log(3.0) log(2.0) log(3.0) log(1.0) log(1.0) log(1.0) log(1.001) log(1.0) 15
        log(1.0) log(1.001)  
        log(1.001) log(1.001)  
  1. aLength of the period in which the time-varying covariate C3(t) has an effect